Advances in immunotherapy of thymic tumors
10.3760/cma.j.cn112434-20201127-00518
- VernacularTitle:胸腺肿瘤免疫治疗的研究进展
- Author:
Chao GAO
1
;
Ji LI
;
Xingrong LIU
;
Naixin LIANG
;
Shanqing LI
Author Information
1. 中国医学科学院 北京协和医院胸外科，北京 100730
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2022;38(2):126-128
- CountryChina
- Language:Chinese
-
Abstract:
Thymic epithelial tumor is a rare anterior mediastinal tumor. Surgery is the most important treatment for thymic tumors. However, non-surgical treatment is still an inevitable choice for unresectable advanced thymic tumors. The traditional treatment methods include chemotherapy and radiotherapy, but the effect is limited. With the development of immunotherapy therapy, some studies have attempted the exploration of immunotherapy for thymic tumors. Because of the low incidence rate of thymic tumors, these studies are mostly small retrospective analyses. This article review the clinical and basic research progress of immunotherapy for thymic tumors
